| Name | Title | Contact Details |
|---|
AudioNet is a National Provider Network that sub-contracts with various Hearing Aid networks throughout the country to give eligible members the best selection of product and service under one network administrator. We have successfully sub-contracted with over 5,000 Audiologists/ENTs nationally to meet the contractual requirements of our customers, as well as the members needs. Mandating only the most qualified providers to service our members and monitoring the quality of products rendered, AudioNet is able to bring a level of Provider Accountability to the Hearing Aid industry that has never before been seen. Negotiating for State of the Art digital products within a National Provider Network allows the eligible member a tremendous benefit enhancement of upto Two (2) Standard Digital Hearing Aids, covered in full. The Fee Schedules, Product Models and Styles, etc., approved for distribution In-Network are outlined on this website.
MedLearning is a Hasbrouck Heights, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Professional Compounding Centers of America is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Echo Therapeutics is developing its Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system. A significant consumer (non-regulated) opportunity also exists for Symphony to be used in the fitness, weight loss and personal lifestyle space. Echo also developed its needle-free skin preparation device as a platform technology that allowed for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.